Search research articles
Contact Us
Filters
Showing results (251-260 of 491) with videos related to
Page
of 50
Sort By:
American Journal of Therapeutics
|
June 11, 2014
Melanoma early detection and awareness: how countries developing melanoma awareness programs could benefit from melanoma-proficient countries
Alberto Wainstein, Salvador Martin Algarra, Lars Bastholt, et al.
Melanoma Research
|
February 20, 2020
The prognostic role of BRAF and WNT pathways activation in kinase inhibitors-naïve clinical stage III cutaneous melanoma
Artur Kowalik, Monika Jurkowska, Ewa Mierzejewska, et al.
Melanoma Research
|
March 30, 2020
BRAF and MEK inhibitors rechallenge as effective treatment for patients with metastatic melanoma
Bożena Cybulska-Stopa, Paweł Rogala, Anna M Czarnecka, et al.
Cancers
|
June 27, 2019
Molecular Comparison of Imatinib-Naïve and Resistant Gastrointestinal Stromal Tumors: Differentially Expressed microRNAs and mRNAs
Azadeh Amirnasr, Caroline M M Gits, Patricia F van Kuijk, et al.
Seminars in Oncology
|
August 12, 2009
Other targetable sarcomas
Veridiana Pires de Camargo, Matt van de Rijn, Roberta Maestro, et al.
JAMA Network Open
|
February 17, 2026
Adjuvant Pembrolizumab for Stage IIB or IIC Melanoma: A Secondary Analysis of a Randomized Clinical Trial
Sancy A Leachman, Jason J Luke, Paolo A Ascierto, et al.
Cancer Immunology, Immunotherapy : CII
|
June 18, 2026
A phase I study evaluating subcutaneous administration of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced solid malignancies
Piotr Rutkowski, Dariusz M Kowalski, Victor Moreno, et al.
Cancers
|
January 11, 2022
Efficacy of Neoadjuvant Targeted Therapy for Borderline Resectable III B-D or IV Stage BRAF <sup>V600</sup> Mutation-Positive Melanoma
Anna M Czarnecka, Krzysztof Ostaszewski, Aneta Borkowska, et al.
The American Journal of Surgical Pathology
|
July 9, 2025
DNA Methylation Profiling Separates SDH-Deficient GISTs From KIT-PDGFRA-Driven GISTs and Identifies Predictive Biomarkers for Targeted Therapy
Małgorzata Chłopek, Jerzy Lasota, Omkar Singh, et al.
Current Oncology (Toronto, Ont.)
|
February 23, 2024
From Molecular Biology to Novel Immunotherapies and Nanomedicine in Uveal Melanoma
Kamil J Synoradzki, Natalia Paduszyńska, Malgorzata Solnik, et al.
Page
of 50
Search research articles
Search
Showing results (251-260 of 491) with videos related to
Sort By:
Page
of 50
American Journal of Therapeutics
|
June 11, 2014
Melanoma early detection and awareness: how countries developing melanoma awareness programs could benefit from melanoma-proficient countries
Alberto Wainstein, Salvador Martin Algarra, Lars Bastholt, et al.
Melanoma Research
|
February 20, 2020
The prognostic role of BRAF and WNT pathways activation in kinase inhibitors-naïve clinical stage III cutaneous melanoma
Artur Kowalik, Monika Jurkowska, Ewa Mierzejewska, et al.
Melanoma Research
|
March 30, 2020
BRAF and MEK inhibitors rechallenge as effective treatment for patients with metastatic melanoma
Bożena Cybulska-Stopa, Paweł Rogala, Anna M Czarnecka, et al.
Cancers
|
June 27, 2019
Molecular Comparison of Imatinib-Naïve and Resistant Gastrointestinal Stromal Tumors: Differentially Expressed microRNAs and mRNAs
Azadeh Amirnasr, Caroline M M Gits, Patricia F van Kuijk, et al.
Seminars in Oncology
|
August 12, 2009
Other targetable sarcomas
Veridiana Pires de Camargo, Matt van de Rijn, Roberta Maestro, et al.
JAMA Network Open
|
February 17, 2026
Adjuvant Pembrolizumab for Stage IIB or IIC Melanoma: A Secondary Analysis of a Randomized Clinical Trial
Sancy A Leachman, Jason J Luke, Paolo A Ascierto, et al.
Cancer Immunology, Immunotherapy : CII
|
June 18, 2026
A phase I study evaluating subcutaneous administration of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced solid malignancies
Piotr Rutkowski, Dariusz M Kowalski, Victor Moreno, et al.
Cancers
|
January 11, 2022
Efficacy of Neoadjuvant Targeted Therapy for Borderline Resectable III B-D or IV Stage BRAF <sup>V600</sup> Mutation-Positive Melanoma
Anna M Czarnecka, Krzysztof Ostaszewski, Aneta Borkowska, et al.
The American Journal of Surgical Pathology
|
July 9, 2025
DNA Methylation Profiling Separates SDH-Deficient GISTs From KIT-PDGFRA-Driven GISTs and Identifies Predictive Biomarkers for Targeted Therapy
Małgorzata Chłopek, Jerzy Lasota, Omkar Singh, et al.
Current Oncology (Toronto, Ont.)
|
February 23, 2024
From Molecular Biology to Novel Immunotherapies and Nanomedicine in Uveal Melanoma
Kamil J Synoradzki, Natalia Paduszyńska, Malgorzata Solnik, et al.
Page
of 50